Wall Street Breakfast Wegovy without the needle sparks Novo surge
5 snips
Dec 23, 2025 Novo Nordisk celebrates as the FDA approves an oral version of Wegovy for obesity management, promising a January launch. Mercedes faces a $150M settlement for its diesel emissions scandal. ByteDance outlines a massive $23B plan for AI investments by 2026, focusing on infrastructure. Meanwhile, the market buzzes with news of stocks like Zim surging on strategic proposals, as the Santa Claus rally hints at a hopeful January effect.
AI Snips
Chapters
Transcript
Episode notes
Oral Wegovy Marks A Breakthrough
- The FDA approved an oral version of Novo Nordisk's Wegovy, a first-in-class GLP-1 pill for obesity.
- Julie Morgan reports trial data showed average weight loss of 16.6% with a daily 25 mg dose.
Market Reacts Quickly To Approval
- Novo Nordisk expects the Wegovy pill to launch in January and shares jumped in pre-market trading.
- Julie Morgan notes the stock rose about 7% in pre-market action on the approval news.
Mercedes To Pay Nearly $150M
- Mercedes-Benz agreed to pay nearly $150 million to settle diesel emissions allegations across U.S. states and territories.
- Julie Morgan summarizes that software reduced emission controls during normal operation on over 211,000 vehicles from 2008–2016.